129 related articles for article (PubMed ID: 29694284)
1. Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study.
Tadrous M; Brahmania M; Martins D; Knowles S; Janssen HLA; Mamdani MM; Juurlink DN; Gomes T
J Manag Care Spec Pharm; 2018 May; 24(5):464-468. PubMed ID: 29694284
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
3. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
[TBL] [Abstract][Full Text] [Related]
4. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
Hidalgo-Mazzei D; Berk M; Cipriani A; Cleare AJ; Florio AD; Dietch D; Geddes JR; Goodwin GM; Grunze H; Hayes JF; Jones I; Kasper S; Macritchie K; McAllister-Williams RH; Morriss R; Nayrouz S; Pappa S; Soares JC; Smith DJ; Suppes T; Talbot P; Vieta E; Watson S; Yatham LN; Young AH; Stokes PRA
Br J Psychiatry; 2019 Jan; 214(1):27-35. PubMed ID: 30520709
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
[TBL] [Abstract][Full Text] [Related]
6. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
[TBL] [Abstract][Full Text] [Related]
7. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Lampertico P; Buti M; Fung S; Ahn SH; Chuang WL; Tak WY; Ramji A; Chen CY; Tam E; Bae H; Ma X; Flaherty JF; Gaggar A; Lau A; Liu Y; Wu G; Suri V; Tan SK; Subramanian GM; Trinh H; Yoon SK; Agarwal K; Lim YS; Chan HLY
Lancet Gastroenterol Hepatol; 2020 May; 5(5):441-453. PubMed ID: 32087795
[TBL] [Abstract][Full Text] [Related]
8. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
[No Abstract] [Full Text] [Related]
9. Ketamine: stimulating antidepressant treatment?
Malhi GS; Byrow Y; Cassidy F; Cipriani A; Demyttenaere K; Frye MA; Gitlin M; Kennedy SH; Ketter TA; Lam RW; McShane R; Mitchell AJ; Ostacher MJ; Rizvi SJ; Thase ME; Tohen M
BJPsych Open; 2016 May; 2(3):e5-e9. PubMed ID: 27703782
[TBL] [Abstract][Full Text] [Related]
10. Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006.
Tu HA; Bos JH; Woerdenbag HJ; Visser ST; Wilschut JC; van Assen S; de Jong-van den Berg LT; Postma MJ
Clin Ther; 2010 Jan; 32(1):133-44. PubMed ID: 20171419
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Chan HL; Fung S; Seto WK; Chuang WL; Chen CY; Kim HJ; Hui AJ; Janssen HL; Chowdhury A; Tsang TY; Mehta R; Gane E; Flaherty JF; Massetto B; Gaggar A; Kitrinos KM; Lin L; Subramanian GM; McHutchison JG; Lim YS; Acharya SK; Agarwal K;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):185-195. PubMed ID: 28404091
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
Dakin H; Sherman M; Fung S; Fidler C; Bentley A
Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study.
Curry MP; Flamm SL; Milligan S; Tsai N; Wick N; Younossi Z; Afdhal NH
J Manag Care Spec Pharm; 2021 Sep; 27(9):1239-1248. PubMed ID: 34105360
[No Abstract] [Full Text] [Related]
14. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
[TBL] [Abstract][Full Text] [Related]
15. Health Care Costs in a Cohort of HIV-Infected U.S. Veterans Receiving Regimens Containing Tenofovir Disoproxil Fumarate/Emtricitabine.
Nelson RE; Ma J; Crook J; Knippenberg K; Nyman H; Paul D; Esker S; LaFleur J
J Manag Care Spec Pharm; 2018 Oct; 24(10):1052-1066. PubMed ID: 30247099
[TBL] [Abstract][Full Text] [Related]
16. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
Boni C; Janssen HLA; Rossi M; Yoon SK; Vecchi A; Barili V; Yoshida EM; Trinh H; Rodell TC; Laccabue D; Alfieri A; Brillo F; Fisicaro P; Acerbi G; Pedrazzi G; Andreone P; Cursaro C; Margotti M; Santoro R; Piazzolla V; Brunetto MR; Coco B; Cavallone D; Zhao Y; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Massetto B; Fung S; Ahn SH; Ma X; Mangia A; Ferrari C
Gastroenterology; 2019 Jul; 157(1):227-241.e7. PubMed ID: 30930022
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.
Funk AL; Lu Y; Yoshida K; Zhao T; Boucheron P; van Holten J; Chou R; Bulterys M; Shimakawa Y
Lancet Infect Dis; 2021 Jan; 21(1):70-84. PubMed ID: 32805200
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load.
Pan CQ; Duan Z; Dai E; Zhang S; Han G; Wang Y; Zhang H; Zou H; Zhu B; Zhao W; Jiang H;
N Engl J Med; 2016 Jun; 374(24):2324-34. PubMed ID: 27305192
[TBL] [Abstract][Full Text] [Related]
19. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
Park ES; Lee AR; Kim DH; Lee JH; Yoo JJ; Ahn SH; Sim H; Park S; Kang HS; Won J; Ha YN; Shin GC; Kwon SY; Park YK; Choi BS; Lee YB; Jeong N; An Y; Ju YS; Yu SJ; Chae HB; Yu KS; Kim YJ; Yoon JH; Zoulim F; Kim KH
J Hepatol; 2019 Jun; 70(6):1093-1102. PubMed ID: 30794889
[TBL] [Abstract][Full Text] [Related]
20. Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region.
Samadi Kochaksaraei G; Castillo E; Osman M; Simmonds K; Scott AN; Oshiomogho JI; Lee SS; Myers RP; Martin SR; Coffin CS
J Viral Hepat; 2016 Jan; 23(1):15-22. PubMed ID: 26192022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
